The aim of this study was to determine rates of positive findings on positron emission tomography (PET) and bone marrow biopsy performed during staging workup for ocular adnexal lymphoma (OAL).
A retrospective review of OAL patients was conducted. Demographics, primary versus secondary OAL, histologic subtype, and findings on PET and bone marrow biopsy performed as part of the initial staging workup for OAL were recorded.
The study included 119 patients with OAL. There were 85 primary and 34 secondary OALs. The main histologic subtypes of lymphoma were mucosa-associated lymphoid tissue (n = 61), follicular (n = 26), diffuse large B-cell (n = 17), and mantle cell (n = 10). Positive PET findings were seen in 42 of 68 patients (62%) with primary OAL and 19 of 24 (79%) with secondary OAL. Positive PET findings were seen in 24 of 47 patients (51%) with mucosa-associated lymphoid tissue, 13 of 17 (76%) with follicular, 14 of 15 (93%) with diffuse large B-cell, and 9 of 10 (90%) with mantle cell lymphoma. Positive findings on bone marrow biopsy were seen in 7 of 59 patients (12%) with mucosa-associated lymphoid tissue, 4 of 23 (17%) with follicular, 1 of 17 (6%) with diffuse large B-cell, and 2 of 9 (22%) with mantle cell lymphoma.
Our findings suggest that a significant proportion of patients with primary and secondary OAL have positive findings on PET and bone marrow biopsy at initial diagnosis, suggesting a reasonable yield for these tests as part of the initial staging workup in patients with a new diagnosis of OAL.
In a large cohort of ocular adnexal lymphoma patients who routinely underwent positron emission tomography and bone marrow biopsies as part of initial staging for lymphoma, positive findings on PET and BM biopsy were found in a significant proportion of patients.
*Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, †Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, ‡Department of Ophthalmology and Visual Sciences, The University of Texas Medical Branch, Galveston, Texas, U.S.A.; §Narayana Nethralaya, Narayana Health City, Bangalore, India; ‖Department of Lymphoma and Myeloma, ¶Department of Radiation Oncology, and #Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.
Accepted for publication August 5, 2016.
Supported in part by the National Institutes of Health through MD Anderson’s Cancer Center Support Grant, CA016672. The funding organization had no role in the design or conduct of this research.
Presented at ASOPRS Fall Symposium on November 12th–13th, 2015 in Las Vegas, NV.
The authors have no financial or conflicts of interest to disclose.
Address correspondence and reprint requests to Bita Esmaeli, M.D., F.A.C.S., Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1488, Houston, Texas 77030. E-mail: firstname.lastname@example.org